First Horizon Advisors’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-2,238
Closed -$20.7K 2343
2024
Q4
$21.1K Sell
2,238
-165
-7% -$1.72K ﹤0.01% 1314
2024
Q3
$25.7K Sell
2,403
-970
-29% -$10.6K ﹤0.01% 1265
2024
Q2
$33.5K Hold
3,373
﹤0.01% 1094
2024
Q1
$39.7K Hold
3,373
﹤0.01% 1067
2023
Q4
$47.9K Buy
3,373
+114
+3% +$1.29K ﹤0.01% 956
2023
Q3
$39.6K Hold
3,259
﹤0.01% 950
2023
Q2
$40.9K Sell
3,259
-597
-15% -$7.08K ﹤0.01% 975
2023
Q1
$42.8K Hold
3,856
﹤0.01% 956
2022
Q4
$47.1K Buy
3,856
+1,048
+37% +$11.8K ﹤0.01% 887
2022
Q3
$28K Hold
2,808
﹤0.01% 1080
2022
Q2
$29K Buy
+2,808
New +$23.1K ﹤0.01% 1140
2022
Q1
Sell
-2,917
Closed -$32K 1904
2021
Q4
$32K Buy
2,917
+113
+4% +$1.26K ﹤0.01% 1109
2021
Q3
$26K Hold
2,804
﹤0.01% 1178
2021
Q2
$26K Sell
2,804
-54
-2% -$527 ﹤0.01% 1027
2021
Q1
$27K Buy
+2,858
New +$44.2K ﹤0.01% 969

Other funds holding FOLD

First Horizon Advisors's FOLD Position: Q1 2025 in Review

First Horizon Advisors sold out of Amicus Therapeutics (FOLD) in Q1 2025, closing a stake of 2,238 shares — an estimated $20.7K sold.

First Horizon Advisors first reported a position in FOLD in Q1 2021 and held it in 15 quarters. The position peaked at $47.9K in Q4 2023. 286 funds tracked by Wall St. Rank hold FOLD as of Q1 2025.

  • First Horizon Advisors reported no remaining Amicus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • First Horizon Advisors sold 2,238 Amicus Therapeutics shares in Q1 2025, an estimated $20.7K.
  • First Horizon Advisors first reported a position in Amicus Therapeutics in Q1 2021 and held it in 15 quarters.
  • First Horizon Advisors's Amicus Therapeutics position peaked at $47.9K in Q4 2023.
  • 286 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2025.

Based on First Horizon Advisors's 13F filing for Q1 2025, filed 28 Apr 2025.